|
MediVas, LLC, Announces Appointment of CFO
SAN DIEGO -- May 19, 2005 -- MediVas, LLC, the leading developer of bioabsorbable polymers used for drug and biologic delivery, announced today the appointment of Joseph Dowling as the Company's Executive Vice President and Chief Financial Officer, reporting directly to the President & CEO. Mr. Dowling has been a Managing Director in Citigroup's middle market corporate finance and mergers and acquisitions team for the last eight years with much of his financial experience focusing on the medical products industry and health care services.
Prior to his tenure at Citigroup, Mr. Dowling held senior management positions with Coopers & Lybrand and KPMG and provided strategic consulting, restructuring, and corporate finance services. He also worked in the corporate finance and real estate groups at CS First Boston.
"Joe's experience as an investment banker in dealing with large financial transactions will add a valuable new dimension to MediVas," said Kenneth Carpenter, President & CEO of the company. "We are pleased to have him join us in undertaking our product licensing, M&A, and investment banking relationships."
About MediVas: Since its founding in 1998, MediVas has had one simple goal - to change the way that pharmaceuticals are delivered. From small molecule drugs to whole proteins, MediVas has developed a novel platform technology that provides solutions to meet each challenge. MediVas polymers are the first of a new generation of absorbable and biocompatible drug and biologic delivery platforms. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical and medical device companies, as well as our own internal product development efforts. Using this platform technology, MediVas is currently focusing its development efforts on various therapeutic areas.
Corporate Headquarters
6275 Nancy Ridge Drive
San Diego, CA 92121
T: (858) 622-2005
F: (858) 366-7301
© MediVas, LLC
|